Ardelyx Inc. (NASDAQ: ARDX) announced that Chief Patient Officer Laura A. Williams sold 10,739 shares of common stock on August 21, 2026, in an automatic sell-to-cover transaction to cover withholding taxes on vested restricted stock units. The sale generated $41,419 at weighted average prices between $3.648 and $3.984 per share, with the weighted average sale price reported at $3.8569.
Following the disposal, Williams retains a direct stake of 367,456 shares in Ardelyx. The transaction occurred as the company’s stock traded near its 52-week low of $3.73, down 43% over the prior six months.
Ardelyx reported a 31% year-over-year increase in second-quarter revenue, reaching a record $118 million, though the company revised guidance for its IBSRELA drug and withdrew full-year revenue targets for XPHOZAH. Options activity surged, with put volume rising to 10,676 contracts.
InvestingPro analysis currently classifies Ardelyx as undervalued, with analysts maintaining a consensus rating of Strong Buy.
